-+ 0.00%
-+ 0.00%
-+ 0.00%

Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60

Benzinga·08/26/2026 11:50:50
语音播报
Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.